2025-11-11
Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals¡¯ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to accelerate scientific innovation. The transaction is expected to close late in Q4 2025.